Trials / Unknown
UnknownNCT03168607
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Phase II Study of FOLFIRI as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Currently, there is no standard second line treatment for patients with neuroendocrine carcinoma. Irinotecan monotherapy or combination regimen has shown promising in previous study. The study was designed to confirm thet FOLFIRI regimen can be used as a second-line regimen for patients with advanced or metastatic neuroendocrine carcinoma who have progressed after first-line chemotherapy with platinum based regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FOLFIRI Protocol | Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W |
Timeline
- Start date
- 2017-05-02
- Primary completion
- 2019-05-02
- Completion
- 2020-05-02
- First posted
- 2017-05-30
- Last updated
- 2017-06-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03168607. Inclusion in this directory is not an endorsement.